Drugs Losing Exclusivity in 2031 & Key Intermediates
9 drugs expire in 2031 (public sources), 8 with recorded synthesis routes; key intermediates of 8 drugs are already available through the Unibest supply network. Generic developers typically secure intermediate supply 2–3 years ahead — use this table for shortlisting and RFQ.
| Drug | Tier | Expiry | Indications | Routes | CAS count | Available |
|---|---|---|---|---|---|---|
| 甲磺酸奥希替尼 Osimertinib Mesylate | A · Act now | 2031 | 非小细胞肺癌 | 4 | 29 | Available ×29 |
| 维贝格隆 Vibegron | C · Watch | 2031 | 膀胱过度活动症、尿失禁 | 2 | 22 | Available ×22 |
| 瑞卢戈利 Relugolix | C · Watch | 2031 | 前列腺癌、平滑肌瘤 | 1 | 12 | Available ×12 |
| 达罗他胺 Darolutamide | B · Position early | 2031 | 激素敏感性前列腺肿瘤、去势敏感性前列腺肿瘤、前列腺癌 | 1 | 9 | Available ×9 |
| 甲苯磺酸卢美哌隆 Lumateperone tosylate | C · Watch | 2031 | 重度抑郁症、抑郁、精神分裂症 | 1 | 9 | Available ×9 |
| 普拉替尼 Pralsetinib | C · Watch | 2031 | 非小细胞肺癌、甲状腺瘤、甲状腺髓样癌 | 7 | 41 | Available ×3 |
| 泽布替尼 Zanubrutinib | A · Act now | 2031 | 华氏巨球蛋白血症、慢性淋巴细胞白血病、滤泡性淋巴瘤 | 1 | 12 | Available ×2 |
| 芦曲泊帕 Lusutrombopag | C · Watch | 2031 | 血小板减少 | 1 | 12 | Available ×1 |
| 司美格鲁肽 Semaglutide | A · Act now | 2031 | 超重、肥胖症、二型糖尿病 | - | - | - |
Frequently asked questions
Which drugs lose exclusivity in 2031?
9 drugs expire in 2031 per public sources: Osimertinib Mesylate, Zanubrutinib, Pralsetinib, Lumateperone tosylate, Darolutamide, Relugolix, etc.
When should we start sourcing intermediates for 2031 launches?
Generic developers typically secure development-scale supply 2–3 years before expiry. 8 of the 9 drugs in this table already have on-sale intermediates in the Unibest network; the rest can be RFQ'd per CAS.
Are route and CAS data verified?
All fields are structured data cross-verified from public sources; intermediates carry registry codes and CAS numbers, and every "Available" badge links to real listings.
Source: cross-verified structured fields · Expiry years are public-source estimates; consult individual agencies for authoritative dates · 2026-09-24